Valuation: Bioventix PLC

Market Cap 87.52M 116M 101M 93.48M 164M 10.91B 168M 1.12B 435M 5.39B 434M 425M 18.7B P/E 2026 *
12.5x
P/E 2027 * -
Enterprise Value 82.62M 109M 95.74M 88.25M 155M 10.3B 158M 1.06B 410M 5.09B 410M 401M 17.65B EV / Sales 2026 *
6.61x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
8.96%
Yield 2027 * -
1 week-4.01%
3 months+21.82%
6 months-6.94%
Current year-12.07%
1 week 1,600
Extreme 1600
1,850
1 month 1,500
Extreme 1500
1,850
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
3,020
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 2003-12-22
Director of Finance/CFO 67 2020-06-30
Director TitleAgeSince
Director/Board Member 67 2010-11-24
Chairman 66 2004-10-31
Director/Board Member 67 2020-06-30
Date Insider Type Main position Quantity % Market Cap.
06-23Buy

Chief Financial Officer

534 0.0102%
04-27Buy

Chief Financial Officer

66 0.0013%
04-19Free

Chief Executive Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.01%-39.09%-56.49% 116M
-0.48%+7.20%-5.65%+3.69% 46.2B
+2.19%+11.71%+393.31%+609.31% 38.71B
+2.53%+13.93%+21.38%-10.96% 31.9B
+1.65%+3.61%+16.04%+55.24% 31.12B
-4.16%-2.58%+8.94%+26.14% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+136.34% 15.05B
+1.00%+10.30%+13.31%+23.36% 13.74B
+3.63%+9.53%+103.97%+106.25% 13.42B
Average +0.74%+7.82%+64.65%+99.21% 23.02B
Weighted average by Cap. +0.75%+8.70%+88.68%+138.02%

Financials

2026 *2027 *
Net sales 12.5M 16.52M 14.48M 13.35M 23.44M 1.56B 23.93M 160M 62.1M 770M 62.03M 60.68M 2.67B -
Net income 7.11M 9.4M 8.24M 7.6M 13.34M 887M 13.61M 91.31M 35.33M 438M 35.29M 34.52M 1.52B -
Net Debt -4.89M -6.47M -5.67M -5.23M -9.18M -610M -9.37M -62.83M -24.31M -302M -24.29M -23.76M -1.05B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
26-06-26 GBX 1,675.00 0.00% 1,002
26-06-25 GBX 1,675.00 -4.29% 4,191
26-06-24 GBX 1,750.00 -2.78% 4,507
26-06-23 GBX 1,800.00 0.00% 12,499
26-06-22 GBX 1,800.00 +3.15% 3,263
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock